Investing.comDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 21:52:31·⟳ 抓取 21:52:51 +20s·⚡ 决策 10-15 21:54:50 +1m59s·11.7 天前
Revolution Medicines胰腺癌新药RASONQUE获欧盟CHMP正面意见，但属预期内程序性里程碑
CHMP正面意见是已公开的加速审评路径下的程序性结果，关键III期OS数据早已披露并经FDA 8月批准验证，无新临床或商业信息；信号发布时美股盘中股价193.04美元、-0.25%，市场确认无预期差，缺乏做多edge；事件为正面也无做空理由。
📄 原文Investing.com↗ 原文
Revolution Medicines receives EU committee backing for pancreatic cancer drug
Nasdaq falls over 1% at the open, S&P and Dow mixed amid tech slide and hot PPI REDWOOD CITY, Calif. - Revolution Medic…
不做 Revolution Medicines（RVMD.US）
CHMP正面意见为加速审评路径下的预期内程序性里程碑，核心III期数据早已公开并经FDA 8月批准验证，无新增临床/商业信息；信号时盘中-0.25%、无放量，已price-in，无做多edge；事件正面且无利空，亦不构成做空催化。后续EC正式批准或欧洲超预期报销落地若带来新事实再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RASONQUE获CHMP推荐欧盟批准是真实但完全在预期内的监管里程碑：数据早已公开、FDA 8月已批、EMA加速审评7月已启动，盘中股价零反应说明已price-in，无正期望交易机会，回避。
消息传播链
- CHMP采纳正面意见建议欧盟集中上市许可，待EC决定；当日美股盘中RVMD 193.04美元(-0.25%)，无异动，市场视为预期内程序性落地市场反应:RVMD盘中-0.25%，盘前+0.03%，量比1.02，无跳空无放量
关键理由
- 正面意见无新增临床信息：RASolute 302的OS HR 0.40等数据此前已驱动FDA批准，CHMP按既定路径走票
- 信号时点盘中股价-0.25%、盘前仅+0.03%，近20日-1.2%且无异动放量，市场直接确认该催化无重定价空间
主要风险
- 若EC批准后公布超预期的德国/法国快速报销或大首单，可能成为新的独立催化（当前无此信息）
- 美国市场早期可及/保险承接延迟的既有报道（STAT 9月）若恶化，会影响核心放量叙事，但与本次欧盟事件无关
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-08 · 影响 weakens
STAT 9月初报道FDA批准后早期可及/保险承接延迟、部分患者需自筹费用；属美国商业化执行层面的逆风，进一步削弱程序性利好的追高价值
检索:Revolution Medicines Rasonque launch access delay insurance reimbursement STAT September 2026 原文 ↗ - 做多前查反向 · 来源 futu行情 · 日期 2026-10-15 · 影响 invalidates
信号发布时盘中-0.25%、盘前+0.03%、量比1.02，无跳空放量，实时价格证据显示市场未将其视为增量利好
检索:RVMD CHMP opinion stock reaction October 15 2026
先例如何影响了这次决策
对本次决策的影响:先例未改变结论；结论由事件预期内属性与实时零价格反应共同锁定为AVOID
方向:未构建先例面板：本次决策不依赖涨幅校准，因为盘中实时价格反应（零波动）已直接证明无edge，强于任何历史类比
涨幅量级:无适用高相似对齐先例；亦无需用先例定tp/sl，因不出腿
形态:监管路径类CHMP意见在数据与FDA批准之后通常为sell-the-news/无反应型程序性事件，与本次盘中零反应一致
工具执行结果 · 成功 7 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 20 ms
{"result": "search_processed_events:agent query=`revolution medicines rasonque daraxonrasib ema chmp positive opinion pancreatic cancer | revolution medicines 欧盟 胰腺癌 daraxonrasib 上市 | rvmd european medicines agency committee posi`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 870 ms
{ - web_search 成功 doubao_search · 1,576 ms
豆包搜索结果（原始查询:Revolution Medicines CHMP positive opinion RASONQUE daraxonrasib October 2026 analyst expected；API SearchType:web） - web_search 成功 doubao_search · 1,598 ms
豆包搜索结果（原始查询:Revolution Medicines EMA CHMP opinion timeline October 2026 expected EU approval daraxonrasib；API SearchType:web） - search_case_library 成功 stock_tools HTTP · 19 ms
{"result": "search_case_library「RVMD.US」—— 与这些标的相关的自家决策案例(本页 10 条,该标的全历史相关记录共 40 条；ENTER 只按该标的自己的腿统计):\n◆ RVMD.US：相关历史决策 40 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 10 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-09-08 UTC 不做 · 事件:STAT报道 Revolution - validate_order 成功 stock_tools HTTP · 7 ms
{
原文全文
展开原文 · 2,132 字
Nasdaq falls over 1% at the open, S&P and Dow mixed amid tech slide and hot PPI
REDWOOD CITY, Calif. - Revolution Medicines Inc. (NASDAQ:RVMD) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for RASONQUE (daraxonrasib) as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
The recommendation is based on results from the Phase 3 RASolute 302 trial, according to a press release statement. The trial evaluated RASONQUE against chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.
In the intent-to-treat population, which included patients with or without an identified tumor RAS mutation, RASONQUE showed a hazard ratio of 0.40 for overall survival compared with chemotherapy. The median overall survival was 13.2 months with RASONQUE compared to 6.7 months for chemotherapy. The median progression-free survival was 7.2 months with RASONQUE compared to 3.6 months with chemotherapy.
The most common adverse reactions in patients treated with RASONQUE were diarrhea (63.1%), dermatitis acneiform (62.4%), stomatitis (55.5%), nausea (50.8%), vomiting (41.6%) and fatigue (33.2%).
The positive opinion underwent an expedited phased review under the EMA’s Cancer Medicines Pathfinder project. If approved by the European Commission, the centralized marketing authorization will be valid in all EU member states and European Economic Area countries Iceland, Norway and Liechtenstein. The authorization would not be applicable in the United Kingdom or Switzerland.
RASONQUE received approval from the U.S. Food and Drug Administration on August 26, 2026 for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Approximately 147,000 people are diagnosed with pancreatic cancer in Europe each year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
REDWOOD CITY, Calif. - Revolution Medicines Inc. (NASDAQ:RVMD) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for RASONQUE (daraxonrasib) as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
The recommendation is based on results from the Phase 3 RASolute 302 trial, according to a press release statement. The trial evaluated RASONQUE against chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.
In the intent-to-treat population, which included patients with or without an identified tumor RAS mutation, RASONQUE showed a hazard ratio of 0.40 for overall survival compared with chemotherapy. The median overall survival was 13.2 months with RASONQUE compared to 6.7 months for chemotherapy. The median progression-free survival was 7.2 months with RASONQUE compared to 3.6 months with chemotherapy.
The most common adverse reactions in patients treated with RASONQUE were diarrhea (63.1%), dermatitis acneiform (62.4%), stomatitis (55.5%), nausea (50.8%), vomiting (41.6%) and fatigue (33.2%).
The positive opinion underwent an expedited phased review under the EMA’s Cancer Medicines Pathfinder project. If approved by the European Commission, the centralized marketing authorization will be valid in all EU member states and European Economic Area countries Iceland, Norway and Liechtenstein. The authorization would not be applicable in the United Kingdom or Switzerland.
RASONQUE received approval from the U.S. Food and Drug Administration on August 26, 2026 for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Approximately 147,000 people are diagnosed with pancreatic cancer in Europe each year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5a75b237bb· 2026-10-15 21:54 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前